Do Antibiotics Raise Blood Sugar Levels?

Certain antibiotics can disrupt blood sugar, but the relationship is more complicated than a simple “yes, they raise it.” Some antibiotics push blood sugar down rather than up, and one class of antibiotics, the fluoroquinolones, can swing it in both directions. Meanwhile, the infection being treated often raises blood sugar on its own, making it easy to blame the drug when the illness deserves the credit. The reality depends heavily on which antibiotic you’re taking, whether you already have diabetes, and what other medications are in the mix.

The Infection Itself Is Often the Culprit

Before pointing the finger at antibiotics, it helps to know that infections are one of the most reliable triggers for high blood sugar. When your body fights off a serious bacterial infection, it mounts a stress response that floods the bloodstream with hormones like cortisol and adrenaline. These hormones make cells more resistant to insulin while simultaneously prompting the liver to dump stored glucose into the blood. The result is what clinicians call stress-induced hyperglycemia, defined as blood glucose above 180 mg/dL in someone who doesn’t otherwise have diabetes.¹ In people who already have diabetes, the spike can be much worse.

This matters because many people notice their blood sugar climbing right around the time they start antibiotics and assume the medication is responsible. Sometimes it is. But often the timing just reflects the peak of the infection itself, or a combination of both factors layered on top of each other. Separating the drug’s effect from the disease’s effect is one of the persistent headaches in studying antibiotic-related blood sugar changes.

Fluoroquinolones and Blood Sugar Swings

Fluoroquinolones are the antibiotic class most convincingly linked to blood sugar problems, and what makes them unusual is that they can cause both dangerously low and dangerously high blood sugar. This isn’t a minor footnote in a drug reference book. The effect was severe enough that one member of the class, gatifloxacin, was pulled from the U.S. and Canadian markets primarily because of its blood sugar risks.

A large study comparing fluoroquinolones to a control antibiotic (azithromycin, which has minimal effect on blood sugar) found that gatifloxacin carried roughly four times the odds of severe hypoglycemia and about four and a half times the odds of severe hyperglycemia in patients with diabetes.² Levofloxacin, which is still widely prescribed, showed roughly double the odds of both severe hypoglycemia and hyperglycemia compared with azithromycin. Ciprofloxacin, another common fluoroquinolone, did not show a statistically meaningful increase in either direction.² A systematic review of fluoroquinolone safety in patients with diabetes confirmed this general ranking, with gatifloxacin carrying the highest dysglycemia risk, followed by levofloxacin.³

So within this single antibiotic family, the risk varies enormously by specific drug. That’s worth knowing if your doctor prescribes a fluoroquinolone and you have diabetes or are already prone to blood sugar instability.

Why Fluoroquinolones Mess with Insulin

The mechanism behind fluoroquinolone-induced blood sugar changes centers on the insulin-producing beta cells in the pancreas. These cells have potassium channels (called KATP channels) that act as a kind of gate for insulin release. When blood sugar rises after a meal, glucose metabolism inside the beta cell causes these channels to close, which triggers a cascade ending in insulin secretion. Certain fluoroquinolones can force those channels shut on their own, independent of blood sugar levels, causing the pancreas to release insulin when it shouldn’t.⁴

Research has shown that gatifloxacin and temafloxacin stimulate insulin secretion and inhibit KATP channel activity in a dose-dependent manner, while levofloxacin has a much smaller effect at the channel level.⁵ That difference at the molecular level matches what doctors see clinically: gatifloxacin causes more blood sugar trouble than levofloxacin, which in turn causes more than ciprofloxacin.

The paradox of fluoroquinolones causing both low and high blood sugar likely comes down to timing and beta-cell exhaustion. An initial surge of inappropriate insulin secretion drives blood sugar down. In some patients, prolonged overstimulation of the beta cells can then lead to dysfunction and inadequate insulin output, flipping the problem to hyperglycemia. This biphasic pattern is part of what made gatifloxacin so dangerous: the direction of the blood sugar change was unpredictable.

Antibiotics That Lower Blood Sugar

The question people usually ask is whether antibiotics raise blood sugar, but a number of antibiotics actually push it the other way. Low blood sugar from an antibiotic can be just as dangerous as high blood sugar, and in some cases more immediately life-threatening.

Trimethoprim-Sulfamethoxazole (Bactrim)

TMP-SMX, commonly sold as Bactrim or Septra, is one of the most prescribed antibiotics worldwide, and it carries an underappreciated risk of hypoglycemia. The sulfamethoxazole component of the drug is structurally similar to sulfonylureas, a class of diabetes medications that works by stimulating pancreatic insulin release.⁶ In effect, taking TMP-SMX can be a bit like taking a mild dose of a diabetes drug you never asked for. Severe hypoglycemia from TMP-SMX is rare, but case reports describe it as potentially life-threatening and sometimes refractory to standard treatment.⁷

The risk is higher in people with kidney problems, because impaired kidneys clear the drug more slowly, leading to higher and longer-lasting blood levels. Elderly patients are also more vulnerable. If you’re taking TMP-SMX for a urinary tract infection or another common indication and you start feeling shaky, sweaty, or confused, low blood sugar is worth considering.

Linezolid

Linezolid is a newer antibiotic reserved for serious infections caused by drug-resistant bacteria. Hypoglycemia from linezolid is rare but can be severe, and it appears to stem from the drug’s effect on mitochondria, the energy-producing structures inside cells. When mitochondria in pancreatic beta cells are impaired, insulin regulation can go haywire.⁸ A case report described recurrent hypoglycemic episodes in an elderly patient who had been on linezolid for over five weeks, with the episodes beginning just days after starting the drug.⁹ Linezolid-induced hypoglycemia tends to appear with prolonged courses rather than short ones, and elderly patients with compromised liver or kidney function face the highest risk.

Erythromycin

Erythromycin, a macrolide antibiotic, has an unusual secondary property: it mimics the gut hormone motilin by binding to the motilin receptor. Motilin normally helps regulate stomach contractions, but it can also stimulate insulin secretion. Researchers have studied whether this motilin-mimicking property could actually improve blood sugar control in people with type 2 diabetes.¹⁰ This is a case where an antibiotic’s metabolic side effect might theoretically be useful, though erythromycin is not used as a diabetes treatment because its primary purpose and side-effect profile don’t make it practical for that role.

A Broader Look at Which Antibiotics Carry Risk

A large-scale analysis of the FDA’s adverse event reporting system looked at which antibiotics were most strongly linked to reported cases of hypoglycemia. The results paint a picture of risk spread across multiple antibiotic families, not just fluoroquinolones. Cefditoren, a cephalosporin antibiotic, showed the strongest signal, with a reporting odds ratio above 14, meaning it appeared in hypoglycemia reports far more often than expected relative to other drugs. Tigecycline, clarithromycin, ertapenem, moxifloxacin, levofloxacin, and linezolid all showed statistically significant associations as well.¹¹

When the analysis adjusted for patients who were also taking sulfonylureas or meglitinides (diabetes drugs that independently lower blood sugar), several of those associations weakened or disappeared. Cefditoren, tigecycline, ertapenem, and clarithromycin still showed significant signals after adjustment, suggesting those antibiotics carry real hypoglycemia risk even without the help of other blood-sugar-lowering medications.¹¹ The takeaway here is that antibiotic-induced blood sugar changes aren’t limited to the drugs that get the most attention for it. If you’re monitoring blood sugar for any reason, being aware that a broader range of antibiotics can contribute is useful.

Drug Interactions That Amplify the Problem

For people already on diabetes medication, the interaction between antibiotics and those drugs can turn a minor blood sugar fluctuation into a dangerous one. Sulfonylureas and meglitinides work by stimulating insulin release. If an antibiotic like TMP-SMX or a fluoroquinolone also stimulates insulin release through a different mechanism, you effectively get a double dose of the same physiological effect, and blood sugar can plummet.

The FDA adverse event data makes this interaction visible. Several antibiotics that showed significant hypoglycemia signals on their own had even stronger associations when patients were simultaneously taking sulfonylureas or meglitinides. This isn’t surprising pharmacologically, but it’s the kind of interaction that can slip through the cracks when the prescribing doctor for the antibiotic doesn’t know what the endocrinologist prescribed, or vice versa. If you’re on medication that lowers blood sugar and you receive an antibiotic prescription, it’s worth flagging that overlap explicitly.

Does Disrupting Gut Bacteria Affect Blood Sugar?

There’s been considerable popular interest in the idea that antibiotics could change blood sugar by disrupting the gut microbiome. The logic sounds reasonable: gut bacteria play a role in metabolism, antibiotics kill gut bacteria, therefore antibiotics could alter metabolism. But the clinical evidence for this pathway is thinner than the enthusiasm would suggest.

A randomized, double-blind, placebo-controlled trial tested this directly in obese adults. Participants received either vancomycin (which dramatically alters gut bacteria), amoxicillin (which changes them less), or a placebo for seven days. Vancomycin reduced bacterial diversity and shifted the composition of gut flora substantially. But despite those microbiome changes, the researchers found no clinically meaningful effect on insulin sensitivity, energy metabolism, systemic inflammation, or gut permeability. Even at follow-up eight weeks later, when the gut microbiome was still significantly altered, whole-body insulin sensitivity remained unchanged.¹²

That doesn’t mean the gut microbiome is irrelevant to metabolic health in the long run, but it does suggest that a standard short course of antibiotics is unlikely to move the needle on your blood sugar through this mechanism alone. The direct pharmacological effects of specific antibiotics on insulin signaling, described in the sections above, are a far more plausible explanation for the blood sugar changes people experience during antibiotic treatment.

Could Long-Term or Repeated Antibiotic Use Raise Diabetes Risk?

A separate question from acute blood sugar changes is whether repeated courses of antibiotics over months or years could increase the long-term risk of developing type 2 diabetes. A large retrospective study following a nationally representative Korean population found a modest but statistically significant association. People who used antibiotics for 90 or more cumulative days had about a 16% higher risk of developing diabetes compared to non-users. Those who had been prescribed five or more different classes of antibiotics had a 14% higher risk compared to those who had only used one class.¹³

These numbers are real, but they come with the enormous caveat that applies to all observational research on this topic: people who take lots of antibiotics tend to be sicker in general. Frequent infections can reflect underlying metabolic dysfunction, immune problems, or lifestyle factors that independently raise diabetes risk. The study adjusted for many of these confounders, but residual confounding is very hard to eliminate. It’s plausible that some of this association reflects the consequences of frequent illness rather than a direct effect of the antibiotics themselves.

There’s also an emerging body of research, still mostly in the early stages, looking at whether antibiotic exposure in early childhood could influence obesity and metabolic risk later in life. The theory is that disrupting the developing gut microbiome during a critical window could have lasting effects on metabolism. Some studies suggest that early-life antibiotic exposure is associated with increased childhood obesity risk.¹⁴ But this is a long way from proving that a course of amoxicillin for an ear infection will give a child diabetes. The evidence is associational, the effects are small, and the confounders are many.

Practical Guidance for People on Antibiotics

If you have diabetes or prediabetes and you’re prescribed an antibiotic, a few things are worth keeping in mind. First, fluoroquinolones carry the most well-documented risk, and the risk varies by specific drug. Ciprofloxacin appears substantially safer than levofloxacin or moxifloxacin in terms of blood sugar effects. If you’re prescribed a fluoroquinolone and you have diabetes, it’s reasonable to ask your doctor whether an alternative class could work for your infection.

Second, TMP-SMX is prescribed casually for common infections like urinary tract infections, and most prescribers don’t think to warn about blood sugar. If you’re on a sulfonylurea or another insulin-stimulating medication, mention it when picking up the prescription.

Third, monitor your blood sugar more frequently while on any antibiotic, not just the ones listed above. The infection itself will tend to push your blood sugar up, and some antibiotics can push it down, creating a tug-of-war that’s hard to predict without checking. You may need temporary adjustments to your diabetes medications during and shortly after the antibiotic course.

Fourth, for people without diabetes, antibiotic-induced blood sugar changes are uncommon enough that routine monitoring isn’t necessary for most standard prescriptions. The exception would be if you’re on a prolonged course (weeks rather than days), you’re elderly, or you have kidney or liver impairment, all of which slow drug clearance and amplify side effects.

Why Hyperglycemia During Antibiotics Is Usually the Infection

Returning to the specific question of whether antibiotics raise blood sugar: most of the drugs with strong evidence of blood sugar effects actually lower it, not raise it. The fluoroquinolones are the notable exception in being able to cause hyperglycemia, and gatifloxacin, the worst offender, is no longer on the market. When someone on antibiotics sees their blood sugar climbing, the most likely explanation in most cases is the infection’s stress response rather than a direct drug effect. The stress hormones released during serious illness can drive blood glucose well above 180 mg/dL even in someone without prior diabetes.¹

Corticosteroids are sometimes prescribed alongside antibiotics for conditions like pneumonia or severe sinusitis, and steroids are potent blood sugar elevators. If you’re seeing high readings while taking an antibiotic and a steroid together, the steroid is the far more likely driver. The antibiotic gets the blame because it’s the drug you associate with treating the illness, but it’s rarely the one raising your glucose.

The Gatifloxacin Story

The history of gatifloxacin is worth knowing because it illustrates how seriously regulators take antibiotic-induced blood sugar disruption. Gatifloxacin was approved in the late 1990s and became widely used for respiratory and urinary tract infections. Post-marketing surveillance began revealing cases of both severe hypoglycemia and severe hyperglycemia, sometimes progressing to diabetic ketoacidosis or hypoglycemic coma. The crude incidence of severe hyperglycemia with gatifloxacin was roughly four times higher than with azithromycin, and in patients with diabetes the odds were even more skewed.²

By 2006, the oral formulation of gatifloxacin was withdrawn from several markets. The episode prompted the FDA and other agencies to add stronger dysglycemia warnings to the labels of remaining fluoroquinolones. It also shifted prescribing behavior: many guidelines now recommend against fluoroquinolones as first-line therapy when safer alternatives exist, partly because of the metabolic risks. For people with diabetes, this history is a practical reason to ask about alternatives whenever a fluoroquinolone is offered for an infection that could be treated with a different class.

1
PubMed Central. Stress-Induced Hyperglycemia: Consequences and Management
2
Clinical Infectious Diseases. Severe Dysglycemia with the Fluoroquinolones: A Class Effect?
3
PubMed Central. How Safe are Fluoroquinolones for Diabetic Patients? A Systematic Review of Dysglycemic and Neuropathic Effects of Fluoroquinolones
4
PubMed. Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells
5
PubMed. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels
6
Endocrine Practice. Bactrim’s Bitter Aftertaste: Trimethoprim-Sulfamethoxazole-Induced Hypoglycemia
7
PubMed Central. Trimethoprim-sulfamethoxazole-induced refractory hypoglycaemia successfully treated with octreotide
8
PubMed Central. Linezolid-Associated Triad of Acute Pancreatitis, Lactic Acidosis, and Hypoglycemia: A Rare Case Report and Literature Review
9
PubMed Central. Linezolid induced hypoglycemia and anemia: A case report
10
PubMed. Erythromycin improves glycaemic control in patients with Type II diabetes mellitus
11
PubMed Central. Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
12
PubMed. Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial
13
PubMed Central. Association between antibiotics use and diabetes incidence in a nationally representative retrospective cohort among Koreans
14
PubMed Central. Early-Life Antibiotics and Childhood Obesity: Yeast Probiotics as a Strategy to Modulate Gut Microbiota